New drug may hold promise for lupus sufferersFor the first time in a half-century, a new drug appears to offer hope to sufferers of lupus, the chronic, autoimmune disease that plagues an estimated 2 million people, mostly women, in the United States.
(AFX UK Focus) 2010-02-09 16:54 UK court rules HGS gene patent invalid -lawyersLONDON, Feb 9 (Reuters) - A British court has upheld a ruling invalidating a patent on a gene sequence held by Human Genome Sciences, handing victory in the case to Eli Lilly which had challenged HGS's patent, lawyers familiar with the case said on Tuesday. The ruling could affect future decisions by UK courts on the scope of biotech patents, they said, and may also influence decisions in other ...
Press ReleaseHIGH WYCOMBE, England, February 8 /PRNewswire/ -- STELARA (ustekinumab) has today been accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for the treatment of moderate to severe plaque psoriasis.(1) STELARA is the first in a novel class of biologics.
Inconsistencies arise in trials linking health to 9/11NEW YORK — As the first cases in a massive battle over illnesses linked to 9/11 near trial, an Associated Press investigation has found that several of the initial 30 suits contain inconsistent or exaggerated claims about how the workers got sick or how much time they spent at ground zero.
Press ReleaseHigh Wycombe, 8 February 2010 – STELARA (ustekinumab) has today been accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for the treatment of moderate to severe plaque psoriasis.1STELARA is the first in a novel class of biologics.
Eight-Year-Old Allergic To HerselfIt's not unusual for a child to get sick and have to go to the hospital, but for one girl, Children's Hospital and Medical Center in Omaha has been home for half of her life, suffering from a mystery disease.
Vitamin D may protect against Crohn’s diseaseThe active form of vitamin D, known as 1,25-dihydroxyvitamin D (1,25D), is able to maintain proper functioning of the immune system that acts as the body's first defense against microbial invaders.
Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical studyAnthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 ...
Evolution on the marchConventional wisdom holds that if you could bring back someone from 40,000 years ago, he or she would blend perfectly well with today's population.